Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study
Author(s) -
Marco Falcone,
Giusy Tiseo,
Cesira Giordano,
Alessandro Leonildi,
M. Menichini,
Alessandra Vecchione,
Mauro Pistello,
Fabio Guarracino,
Lorenzo Ghiadoni,
Francesco Forfori,
Simona Barnini,
Francesco Menichetti,
Sabrina Agostini o Degl'Innocenti,
Greta Barbieri,
Martina Biancalana,
Matteo Borselli,
Nencini Elia,
S. Spinelli,
Rachele Antognoli,
Calsolario Valeria,
Fabio Monzani,
Paterni Simone,
Rubia Baldassarri,
Pietro Bertini,
Brizzi Giulia,
Alessandra Della Rocca,
P Malacarne,
Monfroni Marco,
Chiara Piagnani,
Nicoletta Carpenè,
Laura Carrozzi,
Alessandro Celi,
Massimiliano Desideri,
Marco Gherardi,
Massimiliano Serradori,
Francesco Cinotti,
Alessandro Cipriano,
Naria Park,
Forotti Giovanna,
Alessandro Mengozzi,
Stefano Masi,
Ruberti Francesca,
Sciuto Maria,
Agostino Virdis,
Fabrizio Maggi,
Valentina Galfo
Publication year - 2020
Publication title -
journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa530
Subject(s) - observational study , covid-19 , medicine , virology , microbiology and biotechnology , biology , outbreak , disease , infectious disease (medical specialty)
Background Bacterial and fungal superinfections may complicate the course of hospitalized patients with COVID-19. Objectives To identify predictors of superinfections in COVID-19. Methods Prospective, observational study including patients with COVID-19 consecutively admitted to the University Hospital of Pisa, Italy, between 4 March and 30 April 2020. Clinical data and outcomes were registered. Superinfection was defined as a bacterial or fungal infection that occurred ≥48 h after hospital admission. A multivariate analysis was performed to identify factors independently associated with superinfections. Results Overall, 315 patients with COVID-19 were hospitalized and 109 episodes of superinfections were documented in 69 (21.9%) patients. The median time from admission to superinfection was 19 days (range 11–29.75). Superinfections were caused by Enterobacterales (44.9%), non-fermenting Gram-negative bacilli (15.6%), Gram-positive bacteria (15.6%) and fungi (5.5%). Polymicrobial infections accounted for 18.3%. Predictors of superinfections were: intestinal colonization by carbapenem-resistant Enterobacterales (OR 16.03, 95% CI 6.5–39.5, P < 0.001); invasive mechanical ventilation (OR 5.6, 95% CI 2.4–13.1, P < 0.001); immunomodulatory agents (tocilizumab/baricitinib) (OR 5.09, 95% CI 2.2–11.8, P < 0.001); C-reactive protein on admission >7 mg/dl (OR 3.59, 95% CI 1.7–7.7, P = 0.001); and previous treatment with piperacillin/tazobactam (OR 2.85, 95% CI 1.1–7.2, P = 0.028). Length of hospital stay was longer in patients who developed superinfections ompared with those who did not (30 versus 11 days, P < 0.001), while mortality rates were similar (18.8% versus 23.2%, P = 0.445). Conclusions The risk of bacterial and fungal superinfections in COVID-19 is consistent. Patients who need empiric broad-spectrum antibiotics and immunomodulant drugs should be carefully selected. Infection control rules must be reinforced.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom